Laddar...
Phase I and pharmacokinetic study of erlotinib (OSI-774) in combination with docetaxel in squamous cell carcinoma of the head and neck (SSCHN)
PURPOSE: This phase I study determined the maximal-tolerated dose, dose-limiting toxicities, pharmacokinetics, and recommended dose of erlotinib with docetaxel. PATIENTS AND METHODS: Twenty-eight patients with head and neck cancer were enrolled. Patients were orally given erlotinib (50 mg) daily plu...
Sparad:
| Huvudupphovsmän: | , , , , , , , , , , , |
|---|---|
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
2010
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3828747/ https://ncbi.nlm.nih.gov/pubmed/20490801 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-010-1332-y |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|